The company reported a -100% year-over-year revenue growth rate in 2026Q1, reflecting the total abandonment of its legacy business model while maintaining $1.9 million in quarterly administrative expenses.
| Sales/Revenue | -349.8K | 0 | 1.33M | 1.26M | 1.2M | 1.39M | 1.38M | 1.55M | 1.56M | 1.08M | 616.45K | 0 |
| Revenue Growth % | -125.56% | -100% | 6.19% | 4.45% | -13.57% | 0.96% | -10.9% | -1.02% | 44.98% | 74.8% | - | - |
| Cost of Goods Sold | 299.17K | 158.83K | 1.07M | 1.02M | 929.44K | 976.45K | 987.56K | 1.21M | 1.17M | 829.79K | 73.07K | 0 |
| COGS % of Revenue | - | - | 79.91% | 81.03% | 77.31% | 70.2% | 71.68% | 78.02% | 75.16% | 77.01% | 11.85% | - |
| Gross Profit | -648.97K | -158.83K | 267.83K | 238.19K | 272.73K | 414.52K | 390.2K | 339.91K | 388.01K | 247.76K | 543.38K | 0 |
| Gross Margin % | 185.52% | - | 20.09% | 18.97% | 22.69% | 29.8% | 28.32% | 21.98% | 24.84% | 22.99% | 88.15% | - |
| Gross Profit Growth % | - | -159.3% | 12.44% | -12.66% | -34.21% | 6.23% | 14.79% | -12.4% | 56.61% | -54.4% | - | - |
| Operating Expenses | 9.51M | 7.59M | 5.2M | 15.99M | 9.07M | 9.25M | 12.84M | 19.72M | 7.96M | 2.78M | 466.45K | 31.01K |
| OpEx % of Revenue | - | - | 389.65% | 1273.56% | 754.11% | 664.88% | 932.25% | 1275.11% | 509.43% | 258.19% | 75.67% | - |
| Selling, General & Admin | 7.65M | 7.98M | 4.35M | 7.31M | 6.98M | 8.22M | 11.96M | 16.93M | 8.02M | 2.8M | 466.45K | 31.01K |
| SG&A % of Revenue | - | - | 326.16% | 582.2% | 580.97% | 591.19% | 868.1% | 1094.56% | 513.3% | 260.25% | 75.67% | - |
| Research & Development | 0 | - | - | - | - | - | - | - | - | - | - | - |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income | -10.16M | -7.59M | -4.93M | -15.75M | -8.79M | -8.83M | -12.45M | -19.38M | -7.63M | -3.88M | 76.93K | -31.01K |
| Operating Margin % | 2903.29% | - | -369.56% | -1254.59% | -731.42% | -635.08% | -903.93% | -1253.13% | -488.46% | -359.88% | 12.48% | - |
| Operating Income Growth % | - | -54.05% | 68.72% | -79.16% | 0.46% | 29.07% | 35.73% | -153.92% | -96.79% | -5140.57% | 348.12% | - |
| EBITDA | -9.48M | -7.43M | -4.63M | -15.42M | -8.33M | -8.4M | -12.08M | -18.87M | -7.11M | -3.7M | 76.96K | 144.5K |
| EBITDA Margin % | 2710.32% | - | -347.03% | -1228.32% | -692.63% | -603.54% | -876.46% | -1220.36% | -454.99% | -343.02% | 12.48% | - |
| EBITDA Growth % | -69.25% | -60.62% | 70% | -85.23% | 0.82% | 30.48% | 36.01% | -165.47% | -92.31% | -4902.85% | -46.74% | - |
| D&A (Non-Cash Add-back) | 675K | 158.83K | 300.47K | 329.95K | 466.28K | 438.78K | 378.48K | 506.74K | 522.84K | 181.64K | 26 | 175.51K |
| EBIT | -16.63M | -16.06M | -5.47M | -15.36M | -8.35M | -8.89M | -12.51M | -17.99M | -7.68M | -3.91M | 77.51K | -102.37K |
| Net Interest Income | -1.4M | -1.46M | -2.44M | -1.35M | -3.58M | -200.48K | -168.76K | -608.33K | -310.34K | -136.74K | 575 | 0 |
| Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | 4.31K | 1.37K | 575 | 0 |
| Interest Expense | 0 | - | - | - | - | - | - | - | - | - | - | - |
| Other Income/Expense | 0 | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | -19.41M | -17.52M | -7.9M | -16.71M | -11.93M | -9.09M | -12.68M | -18.07M | -8.05M | -4.05M | 77.51K | -31.01K |
| Pretax Margin % | 5549.87% | - | -592.72% | -1330.51% | -992.44% | -653.54% | -920.29% | -1168.6% | -515.42% | -375.82% | 12.57% | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 21.93K | -175.5K |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 28.29% | 566.02% |
| Net Income | -19.52M | -18.26M | -7.9M | -16.71M | -11.93M | -9.09M | -12.68M | -18.07M | -7.77M | -3.46M | 55.58K | -31.01K |
| Net Margin % | 5579.32% | - | -592.72% | -1330.51% | -992.44% | -653.54% | -920.29% | -1168.6% | -497.61% | -321.5% | 9.02% | - |
| Net Income Growth % | -116.42% | -131.05% | 52.69% | -40.03% | -31.25% | 28.31% | 29.83% | -132.44% | -124.41% | -6332.86% | 279.26% | - |
| Net Income (Continuing) | -19.41M | -17.52M | -7.9M | -16.71M | -11.93M | -9.09M | -12.68M | -18.07M | -8.05M | -4.05M | 55.58K | -102.37K |
| Discontinued Operations | -103.02K | -742.1K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -862.2K | -585.39K | 0 | 0 |
| EPS (Diluted) | -2.18 | -5.64 | -8.44 | -1.59 | -1.36 | -1.09 | -1.61 | -2.41 | -1.08 | -0.53 | 0.01 | -0.18 |
| EPS Growth % | -33.01% | 33.18% | -430.82% | -16.91% | -24.77% | 32.3% | 33.2% | -123.15% | -103.77% | -4962.39% | 106.06% | - |
| EPS (Basic) | - | -5.64 | -8.44 | -1.59 | -1.36 | -1.09 | -1.61 | -2.41 | -1.08 | -0.53 | 0.01 | -0.18 |
| Diluted Shares Outstanding | 8.96M | 3.21M | 936.61K | 10.53M | 9.33M | 8.49M | 7.95M | 7.51M | 7.2M | 6.5M | 5.11M | 175K |
| Basic Shares Outstanding | 8.96M | 3.21M | 936.61K | 10.53M | 9.33M | 8.49M | 7.95M | 7.51M | 7.2M | 6.5M | 5.11M | 175K |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - |
Imminent liquidity exhaustion
As reported in the most recent quarterly financial statements, ALBT experienced a -100% year-over-year revenue growth rate, effectively signaling the total cessation of its legacy consulting and real estate service operations as the firm attempts a pivot toward a high-risk biotechnology licensing model.
The complete disappearance of top-line revenue suggests that the company's previous business segments are no longer viable or have been intentionally abandoned. Investors should interpret this as a total reset of the firm's operational profile, leaving no recurring revenue base to support ongoing research activities.
Based on the company's latest income statement, the firm continues to incur significant SG&A expenses despite generating zero revenue, with quarterly overhead reaching $1.9 million in 2026Q1, highlighting a structural misalignment between current administrative spending and the lack of commercialized clinical assets.
The persistence of high SG&A costs in the absence of revenue indicates a heavy reliance on external funding to maintain corporate infrastructure. This cost structure appears unsustainable without an immediate and substantial capital infusion to support the company's stated R&D objectives.
According to recent SEC filings, the company reported a net loss of $4.5 million in 2026Q1, a figure that underscores the poor quality of earnings as the firm lacks any core operating income to offset its mounting clinical development and administrative expenses.
The volatility in net income, which has swung between significant losses and anomalous positive figures in prior periods, suggests that reported results are heavily influenced by non-operating items rather than core business performance. The absence of consistent profitability warrants extreme caution regarding the firm's long-term viability.
As indicated by the reported cash balance of only $109,091, the company faces a critical liquidity inflection point that suggests the current market valuation may not fully account for the high probability of severe shareholder dilution or potential insolvency in the near term.
Short-term survival appears entirely dependent on the company's ability to secure non-dilutive funding or strategic partnerships, which remains unproven. The disconnect between the firm's ambitious biotech pipeline and its precarious financial position suggests that the market may be underestimating the risk of total capital loss.
Quick answers to the most common questions about buying ALBT stock.
For fiscal year 2025, Avalon GloboCare Corp. (ALBT) reported total revenue of $0.0M.
Avalon GloboCare Corp. (ALBT) reported a net loss of $18.3M for the fiscal year ending 2025.